Higher CD3+ and CD34+ cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 107-114

  Gaziev, J ^a   Isgro A ^a   Marziali, M ^a   Daniele, N ^a   Gallucci, C ^a   Sodani, P ^a   Simone, M D ^a   Adorno, G ^a   Paciaroni, K ^a   Andreani, M ^a   Lanti, A ^a   Del Proposto, G ^a   Testi, M ^a   De Angelis, G ^a   Roveda, A ^a   Alfieri, C ^a   Saltarelli, F ^a   Lucarelli, G ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

acute GVHD; CD34+ cell dose; CD3+ cell dose; children; thalassemia

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GABEXATE MESILATE; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL LIPASE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE PANCREATITIS; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CD3+ CELL DOSE; CD34+ CELL DOSE; CELL COMPOSITION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER DYSFUNCTION; LOBAR PNEUMONIA; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTINUCLEAR CELL; NEUROTOXICITY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEIZURE; T LYMPHOCYTE; THALASSEMIA; VIRUS REACTIVATION;

ACUTE DISEASE; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD3; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; MALE; METHOTREXATE; METHYLPREDNISOLONE; MYELOABLATIVE AGONISTS; SIBLINGS; THALASSEMIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855729817     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.3     Document Type: Article

References (41)

1. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-844. (Pubitemid 23267211)
2. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34+ selected from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells? Blood 2001; 98: 2352-2357.
3. Gaziev D, Polchi P, Galimberti M, Angelucci E, Giardini C, Baronciani D et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997; 63: 854-860. (Pubitemid 27150593)
4. Di Bartolomeo P, Santarone S, Di Bartolomeo E, Olioso P, Bavaro P, Papalinetti G et al. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol 2008; 83: 528-530. (Pubitemid 351874867)
5. Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and class II beta Thalassemia major. Biol Blood Marrow Transplant 2008; 14: 301-308. (Pubitemid 351218201)
6. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host-disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
7. Hahn T, McCarthy PL, Zhang MJ, Wang D, Arora M, Frangoul H et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukaemia. J Clin Oncol 2008; 26: 5728-5734.
8. Paulin T. Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant 1992; 6: 48-54.
9. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
10. Ringden O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell dose. Br J Haematol 2003; 121: 874-885. (Pubitemid 36760306)
11. Rocha V, Carmagnat MV, Chevret OF, Flinois O, Bittencourt H, Esperou H et al. Influence of bone marrow lymphocyte subset on outcome after HLA-identical sibling transplants. Exp Haematol 2001; 29: 1347-1352. (Pubitemid 33033312)
12. Wojnar J, Giebel S, Krawczyk-Kulis M, Markiewicz M, Kruzel T, Wylezol I et al. Acute graft-versus-host disease. The incidence and risk factors. Ann Transplant 2006; 11: 16-23.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote G, Gudat F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
14. Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Donnorso MP et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010; 115: 4597-7604.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institute of health consensus development project on criteria for clinical trials in chronic graftversus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005; 11: 945-955.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risk: new representation of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
19. Kaplan ER, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
20. Fine JP, Gray RJ. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
21. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2009. http://www.R-project. org.
22. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose. Bone Marrow Transplant 2003; 31: 839-845. (Pubitemid 36675738)
23. Lowenberg B, Wagemaker G, van Bekkum DW, Sizoo W, Sintnicolaas K, Hendriks WD et al. Graft-versus-host disease following transplantation of 'one log' T-lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986; 1: 133-140.
24. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graftversus-host disease. Blood 1986; 68: 770-773. (Pubitemid 16008184)
25. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100: 724-727. (Pubitemid 34761147)
26. Bittencourt H, Rocha V, Chevret S, Sociè G, Espèrou H, Devergie A et al. Association of CD34 cell dose with haematological recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-2733. (Pubitemid 34525358)
27. + marrow cell dose on outcome of HLA-identical sibling bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27: 575-580. (Pubitemid 32401453)
28. Rocha V, Myriam L, Gluckman E, Powles R, Arcese W, Bacigalupo A et al. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukaemia in first complete remission: results of a European Survey. J Clin Oncol 2002; 20: 4324-4330. (Pubitemid 35266293)
29. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470. (Pubitemid 29380428)
30. Lonnqvist B, Aschan J, Ljungman P, Ringden O. Long-term cyclosporin therapy may decrease the incidence of chronic graft-versus-host disease. Br J Haematol 1990; 74: 547-548. (Pubitemid 20122768)
31. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002; 30: 161-165. (Pubitemid 34993855)
32. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230. (Pubitemid 23306323)
33. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotreaxate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391-2398.
34. Storb P, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisolone in prevention of acute graft-versus-host disease in patients undergoing marrow transplantation? Blood 1990; 76: 1037-1045. (Pubitemid 20295520)
35. Hoyt R, Ritchie DS, Roberts AW, Macgregor L, Curtis DJ, Szer J et al. Cyclosporine, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplant. Bone Marrow Transplant 2008; 41: 651-658. (Pubitemid 351524004)
36. Bernaudin F, Sociè G, Kuentz M, Chevret S, Duval M, Bertrand Y et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle-cell disease. Blood 2007; 110: 2749-2756. (Pubitemid 47523201)
37. Ko CW, Gooley T, Schoch HG, Myerson D, Hackman RC, Shulman HM et al. Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. Bone Marrow Transplant 1997; 20: 1081-1086. (Pubitemid 28043421)
38. Salomone T, Tosi P, Raiti C, Stanzani M, Leopardi G, Miglio F et al. Clinical relevance of acute pancreatitis in allogeneic hematopoietic stem cell (bone marrow or peripheral blood) transplants. Digest Dis Sci 1999; 44: 1124-1127. (Pubitemid 29297214)
39. Barker CC, Anderson RA, Sauve RS, Butzner JD. GI complications in pediatric patients post-BMT. Bone Marrow Transplant 2005; 36: 51-58. (Pubitemid 40946050)
40. Foulis AK, Farquharson MA, Sale GE. The pancreas in acute graft-versus-host disease in man. Histopathology 1989; 14: 121-128. (Pubitemid 19068248)
41. Washington K, Gossage DL, Gottfried R. Pathology of the pancreas in severe combined immunodeficiency and DiGeorge syndrome: acute graft-versus-host disease and unusual viral infections. Hum Pathol 1994; 25: 908-914. (Pubitemid 24292407)